Johnson & Johnson

Johnson & Johnson’s MedTech spin‑off reshapes device innovation, accelerates FDA paths, and aims to unlock shareholder value in personalized medicine.

Johnson & Johnson’s Q1 earnings reveal strong profitability and a growing pipeline of gene‑editing, bispecific antibody and targeted kinase therapies, while navigating U.S. drug‑pricing and tariff policy.

Johnson & Johnson’s $500 M co‑funding with Royalty Pharma to advance JNJ‑4804 and EMA approval of subcutaneous Darzalex highlight its dual‑track strategy, expanding inflammatory disease and multiple‑myeloma reach while balancing risk and growth pros…

Johnson & Johnson’s Q1 2026 outlook: modest revenue lift, EPS dip, and new oral psoriasis drug PJ‑102 poised for market success amid Humira patent cliff and strategic M&A moves.

Long‑term Phase 3 data show Johnson & Johnson’s oral ICOTYDE delivers durable, high PASI‑90/100 clearance with a low infection rate and mild side‑effects – a promising new option for moderate‑to‑severe plaque psoriasis.

Johnson & Johnson’s Brazil OTC strategy and U.S. talc litigation impact—key insights on market share, pricing, legal risks and growth plans.

Johnson & Johnson’s latest M&A earn‑out moves, a retracted Lancet talc study, and rising immunotherapy deals highlight its blend of legacy scrutiny and oncology innovation, drawing value‑focused investors.

Johnson & Johnson’s steady stock and robust financials shine amid value‑based reimbursement shifts, showing how its diversified portfolio and digital strategy keep it ahead of rising costs.

J&J’s new oral psoriasis drug Icotyde earns FDA approval, offering patients a once‑daily pill with proven IL‑23/IL‑17 inhibition and comparable efficacy to injectables.

Johnson & Johnson’s recent share dip is linked to FTC scrutiny over Darzalex’s patent expiration, highlighting regulatory risks and the firm’s R&D‑driven turnaround strategy.